Platelet is an Unfavorable Prognostic Biomarker and Associated with Leukemia Stem Cells and Immunomodulatory Factors in Acute Myeloid Leukemia

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Jul 15

PMID 37453949

Authors

Qing Zhang

Haotian Yan

Xiyang Ren

Linlin Liu

Juan Wang

Lulu Zhang

Yi Dong

Hui Qin

Qianshan Tao

Zhimin Zhai

Affiliations

Soon will be listed here.

Abstract

Many clinical features, besides cytogenetic and molecular abnormalities, can affect the prognosis of the patients with acute myeloid leukemia (AML). Within this context it remains unclear if and how platelet counts affect the outcome of AML patients. In the present study, we examined the platelet counts at diagnosis in 633 newly diagnosed adult patients with AML from January 2010 to April 2021, and divided the cases into the group with low level of platelet counts (≤30×10/L, n=316) and high level of platelet counts (>30×10/L, n=317) according to the median platelet counts. We then validated the prognostic significance and potential mechanism of platelet counts on the relevance of spectral features for diagnostic risk stratification, initial induction therapy response, treatment effect maintenance, long-term survival, leukemia stem cells (LSCs) proportion, immunomodulatory cytokines level and immune cell subsets proportion. The results suggested that AML patients with a high level of platelet counts at diagnosis were associated with a high-risk molecular cytogenetic stratification, low complete remission (CR) rate, poor leukemia free survival (LFS), high proportion of LSCs, high level of transforming growth factor-β (TGF-β) and interleukin-1β (IL-1β), high proportion of regulatory T cells (Tregs) and monocytic myeloid-derived suppressor cells (M-MDSCs). It was demonstrated that platelet might be an unfavorable prognostic biomarker and was associated with LSCs and immunomodulatory cytokines as well as immune cell subsets in AML.

Citing Articles

Prognostic impact of initial platelet count and post-induction platelet recovery in elderly AML patients: associated with circulating cytokines.

Ling C, Cao N, Niu X, Xu S, Gong W, Bao W Front Oncol. 2025; 15:1534158.

PMID: 40078187 PMC: 11897575. DOI: 10.3389/fonc.2025.1534158.

References

Tao Q, Pan Y, Wang Y, Wang H, Xiong S, Li Q . Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int J Cancer. 2015; 137(10):2384-93. DOI: 10.1002/ijc.29563. View

Wang H, Tao Q, Wang Z, Zhang Q, Xiao H, Zhou M . Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia. J Immunol Res. 2021; 2020:7363084. PMC: 7769680. DOI: 10.1155/2020/7363084. View

Zhang Q, Dai K, Bi L, Jiang S, Han Y, Yu K . Pretreatment platelet count predicts survival outcome of patients with non-M3 acute myeloid leukemia. PeerJ. 2018; 5:e4139. PMC: 5742276. DOI: 10.7717/peerj.4139. View

Zhang Y, Gu H, Chen Q, Zhang Y, Cheng H, Yang J . Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia. Acta Haematol. 2019; 143(1):9-18. DOI: 10.1159/000500230. View

Trafalis D, Poulakidas E, Kapsimali V, Tsigris C, Papanicolaou X, Harhalakis N . Platelet production and related pathophysiology in acute myelogenous leukemia at first diagnosis: prognostic implications. Oncol Rep. 2008; 19(4):1021-6. View

Foss B, Bruserud O . Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost. 2008; 99(1):27-37. DOI: 10.1160/TH07-04-0240. View

Semple J, Italiano Jr J, Freedman J . Platelets and the immune continuum. Nat Rev Immunol. 2011; 11(4):264-74. DOI: 10.1038/nri2956. View

Kaushansky K . The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115(12):3339-47. PMC: 1297257. DOI: 10.1172/JCI26674. View

Huang C, Zhu X, Shen Y, Wu D, Ji Y, Ge N . Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res. 2021; 9(1):19. PMC: 7981986. DOI: 10.1186/s40364-021-00274-z. View

10.

Polasky C, Wendt F, Pries R, Wollenberg B . Platelet Induced Functional Alteration of CD4 and CD8 T Cells in HNSCC. Int J Mol Sci. 2020; 21(20). PMC: 7588893. DOI: 10.3390/ijms21207507. View

11.

Li J, Huang Y, Basch R, Karpatkin S . Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost. 2001; 85(2):204-6. View

12.

Ottaviani E, Franchini A, Kletsas D . Platelet-derived growth factor and transforming growth factor-beta in invertebrate immune and neuroendocrine interactions: another sign of conservation in evolution. Comp Biochem Physiol C Toxicol Pharmacol. 2001; 129(4):295-306. DOI: 10.1016/s1532-0456(01)00211-3. View

13.

Placke T, Orgel M, Schaller M, Jung G, Rammensee H, Kopp H . Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2011; 72(2):440-8. DOI: 10.1158/0008-5472.CAN-11-1872. View

14.

Cluxton C, Spillane C, OToole S, Sheils O, Gardiner C, OLeary J . Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade. PLoS One. 2019; 14(3):e0211538. PMC: 6433214. DOI: 10.1371/journal.pone.0211538. View

15.

Morrell C, Aggrey A, Chapman L, Modjeski K . Emerging roles for platelets as immune and inflammatory cells. Blood. 2014; 123(18):2759-67. PMC: 4007605. DOI: 10.1182/blood-2013-11-462432. View

16.

Bent R, Moll L, Grabbe S, Bros M . Interleukin-1 Beta-A Friend or Foe in Malignancies?. Int J Mol Sci. 2018; 19(8). PMC: 6121377. DOI: 10.3390/ijms19082155. View

17.

Hsu H, Lee Y, Tsai W, Ho C, Wang S . Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002; 63(1):64-9. DOI: 10.1159/000065722. View

18.

Kerr R, Stirling D, Ludlam C . Interleukin 6 and haemostasis. Br J Haematol. 2001; 115(1):3-12. DOI: 10.1046/j.1365-2141.2001.03061.x. View

19.

Han Z, Li Y, Yang L, Cheng H, Liu X, Chen H . Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy. Molecules. 2022; 27(1). PMC: 8746913. DOI: 10.3390/molecules27010137. View

20.

Winkler I, Wilczynska B, Bojarska-Junak A, Gogacz M, Adamiak A, Postawski K . Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance. J Ovarian Res. 2015; 8:39. PMC: 4513978. DOI: 10.1186/s13048-015-0164-0. View